Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Protagonist Therapeutics Inc shares valued at $979,480 were sold by Waddill William D. on Oct 10 ’25. At $81.62 per share, Waddill William D. sold 12,000 shares. The insider’s holdings dropped to 5,130 shares worth approximately $0.4 million following the completion of this transaction.
Also, WILLIAM WADDILL purchased 12,000 shares, netting a total of over 804,480 in proceeds.
Before that, Waddill William D. had sold 4,000 shares from its account. In a trade valued at $257,000, the Director traded Protagonist Therapeutics Inc shares for $64.25 each. Upon closing the transaction, the insider’s holdings decreased to 4,000 shares, worth approximately $0.4 million.
As published in their initiating research note from Barclays on September 17, 2025, Protagonist Therapeutics Inc [PTGX] has been an Overweight and the price target has been revised to $72. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid September. As of June 17, 2025, Citigroup has initiated its “Buy” rating for PTGX. Earlier on December 06, 2024, Goldman initiated its rating. Their recommendation was “a Neutral” for PTGX stock.
Analyzing PTGX Stock Performance
On last trading session, Protagonist Therapeutics Inc [NASDAQ: PTGX] rose 1.51% to $77.85. The stock’s lowest price that day was $76.75, but it reached a high of $78.74 in the same session. During the last five days, there has been a surge of approximately 5.22%. Over the course of the year, Protagonist Therapeutics Inc shares have jumped approximately 61.51%. Shares of the company reached a 52-week high of $93.25 on 10/10/25 and a 52-week low of $33.70 on 02/25/25.
Support And Resistance Levels for Protagonist Therapeutics Inc (PTGX)
According to the 24-hour chart, there is a support level at 76.82, which, if violated, would cause prices to drop to 75.79. In the upper region, resistance lies at 78.81. The next price resistance is at 79.77. RSI (Relative Strength Index) is 60.84 on the 14-day chart, showing neutral technical sentiment.
Is Protagonist Therapeutics Inc subject to short interest?
Stocks of Protagonist Therapeutics Inc saw a sharp steep in short interest on 2025-10-15 dropping by -0.35 million shares to 6.31 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 6.66 million shares. A decline of -5.5% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.06 of the overall float, the days-to-cover ratio (short ratio) decline to 4.06.
Which companies own the most shares of Protagonist Therapeutics Inc (PTGX)?
In terms of Protagonist Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 88 in the next 12 months, up nearly 14.75% from the previous closing price of $76.69. Analysts anticipate Protagonist Therapeutics Inc stock to reach 112 by 2025, with the lowest price target being 72. In spite of this, 4 analysts ranked Protagonist Therapeutics Inc stock as Buy at the end of 2025. On December 06, 2024, BMO Capital Markets assigned a price target of “an Outperform” to the stock and initiated coverage with a $62.
